Therapeutic antibodies are an important part of Biopharmaceuticals. They are highly innovative and specifi c drugs. Additionally, they play a challenging role in new demands in diagnostics because they disturb conventional antibody-based tests, such as immunoassays. The recovery ELISA is a newly developed immunoassay technology for monitoring such therapeutic antibodies or comparable biologics during the therapy. The recovery ELISA determines three results in one test: the free level of antigen (if available in serum), the level of therapeutic antibody and the specifi c dose-response interaction. The free level of antigen is the amount that can be measured in the immunoassay, as it exists unmasked under assay conditions. The relationship between therapeutic antibody level and neutralization rate of target protein is shown by the so-called ' recovery curve ' . The recovery ELISA is demonstrated with the example of Omalizumab/IgE.
Introduction
Therapeutic antibodies (TA) have an increasing signifi cance in clinical use and a huge fi nancial impact in the healthcare systems worldwide. TA work against human antigens (specifi c target proteins) to inhibit their disease-causing effect. Many clinical studies on TA are currently being carried out and will affect treatments of various diseases areas, e.g., autoimmune and oncological diseases. As TAs are applied over a long time in relative high dosage, an analytical monitoring of the lasting concentrations in each patient should be realized. However, such diagnosis during TA treatment is always a challenge because in many cases measurement of target protein is interfered with by TA in the sample.
The aim of the present work was to develop an in vitro procedure for the reliable determination of both the available therapeutic antibody and the free level of the target antigen in serum samples by use of one sandwich assay. Therefore, it was fi rst investigated how the therapeutic antibody infl uences the antigen calibration curves of a sandwich assay. Second, a quantifi able correlation between the dosage of TA and its effects on the estimation of the target antigen was sought for. Third, an internal calibration procedure was developed to enable the measurement of TA and free antigens in unknown samples. The application of these principles was shown in samples with additional amounts of components to be estimated. The innovative immunoassay principle called recovery ELISA is demonstrated with the example of Omalizumab (TA)/IgE (antigen).
Materials and methods

Materials
For demonstrating the principles of recovery ELISA, Omalizumab was used as the therapeutic antibody. It is a recombinant humanized monoclonal antibody (anti-IgE) for the treatment of IgE-mediated allergies. The main application area is allergic bronchial asthma. As an antibody it binds and neutralizes the immunoglobulin of the E-type (IgE), which is responsible for the activation of allergic reactions (1 -3) .
The following materials were used: 
Method
An immunoassay was designed for calibration curves of IgE (antigen) with further addition of Omalizumab (TA) on a 96-well precoated microplate. IgE standard (25 μ L/well), TA (25 μ L/well) and signal antibody (50 μ L/well) were pipetted as duplicates into the cavities of the microplate. The concentration range of the IgE calibrators was 0 -287 ng/mL, rising from row A to H (A: 0; B: 25; C: 38; D: 57; E: 85; F: 127; G: 191 and H: 287 ng/mL IgE). The TA addition of 0.00 -7.20 μ g/mL was pipetted into the strips 1 + 2 up to the strips 11 + 12 (1 + 2: 0.00; 3 + 4: 0.45; 5 + 6: 0.90; 7 + 8: 1.80; 9 + 10: 3.60 and 11 + 12: 7.20 μ g/mL Omalizumab).
The plate was incubated for 18 h at 2 -8 ° C in darkness. Cavities were washed three times with washing buffer. Then 100 μ L of chromogen solution was added to each well of the microplate. Subsequently, the plate was incubated for 30 min in dark at room temperature and the reaction was stopped by adding stopping solution (25 μ L/well). The plate with an absorbance at 450 nm was then read using a spectrophotometer (Spectra Flour, TECAN, Crailsheim, Germany). Measured values were calculated using XLSTAT-Pro (Addinsoft SARL, Paris, France) for a two-dimensional (2D) evaluation. The estimation of components in analytical samples is performed by an expanded procedure, descripted in the following part.
Results
From the results of the above-described immunoassay procedure, the extinctions (O.D. = optical density) were measured as duplicates and the averages were calculated. With an increasing concentration of TA, a decrement in the curves was observed. It becomes evident, that the O.D. in the presence of TA is no longer a function only of x but also of y as a second independent variable. While the original calibration curve of the IgE-ELISA is plotted with two coordinates within 2D, three dimensions (3D) in space are required to plot the response against x and y, yielding inclined planes in space. This aspect was taken into account by fi tting the response to a Michaelis-Menten model for competitive inhibition with the two independent variables x and y (see eq. [4] in the discussion). By the advanced fi tting procedure of Reich (4) , the model coeffi cients were estimated with an acceptable range of confi dence. The law of mass action might also describe immunoassays mathematically. But Strohner et al. have observed a decrease of the binding constant with increasing concentration of antibody in competitive radioimmunoassays (5) .
As a next step, the set of data were fi tted by non-linear regression using the Michaelis-Menten model:
with E = O.D., E max = maximum O.D., K m = Michaelis constant, x = antigen and u = non-specifi c binding, estimated experimentally. For the calibration curve without TA (reference curve, see Figure 1A : TA = 0.0 μ g/mL), the following result is then obtained:
with a high coeffi cient of determination (99.85 % ). After subtracting the non-specifi c binding the net extinction E x is obtained:
Then the inverse of eq. [1] can be used for the estimation of x (IgE) in samples without TA:
In the presence of TA, a smaller concentration x a is calculated using eq. [1a] due to the diminished O.D. x a is the recovered concentration of antigen, which is not bound by TA. Figure 1B shows the concentration x a of recovered IgE dependent on its known concentration x. A series of straight lines is observed. Their slope dx a /dx is diminished with increasing concentration of TA. The fraction of recovered x a , expressed by x a /x, seems to directly dependent on the concentration of TA. Using the 3D model (4) , an inhibition constant K i describes such an infl uence. By inversion of eq. [4] for x and some further transformations x a /x is expressed by:
Therefore, x a /x is denoted as the ' recovery ' (rec), in this model which is only dependent on the concentration of TA = y:
For each concentration of TA, the mean of the recovery was calculated and plotted in dependence of TA = y (see Figure 2 ). It was possible to obtain a function for the recovery by non-linear regression:
Recovery function, with p 1 = coeffi cient of inhibition and p 2 = correcting factor. This resulted in:
with a high coeffi cient of determination (99.88 % ). In Figure 2 , the mean rec of a set of antigen concentration is shown in dependence of TA in the form of a so-called ' recovery curve ' . The same relationship between recovery and TA concentration, which has been described for the experimental investigations (Figure 2 ), has to be expected in analytical samples. For the implementation a further step became necessary to design an assay for analytical samples based on the recovery principle. In the case of analytical samples only x a can be calculated from the O.D. by eq. [1a]. x a is that amount of IgE which is bound by the capture antibody on the microplate.
As the total concentration x of IgE is not known in analytical samples, rec remains unknown. Therefore, an expanded procedure is necessary to evaluate such samples. It will be realized by an internal calibration to get the rec values. By adding known amounts h of IgE x a is enlarged to x a (h). Then becomes rec = (x a (h) -x a )/h. If several additions of h are made, a linear function x a (h) = a + rec × h may be fi tted by linear regression yielding the slope rec and a as a regression parameter, similar to x a . Then it will be also possible to calculate the TA concentration in unknown samples from the inverse of eq. [3] .
For this purpose an immunoassay was designed for analytical samples on a 96-well pre-coated microplate with an area for calibration (strip 1 -4) and an area for samples (strip 5 -12). On the sample area the described addition of known concentrations h of IgE to the samples was running (see Figure 3 ) .
On the calibrator area (strip 1 -4) IgE calibrator (25 μ L/well), TA calibrator (25 μ L/well) and signal antibody (50 μ L/well) were pipetted as duplicates into the cavities. The concentration range of the IgE calibrators was 0 -288 ng/mL, rising from row A to H. The TA calibrators are in the range of 0.00 -7.20 μ g/mL.
Into the cavities of the sample area (strip 5 -12) sample (25 μ L/well), IgE calibrator for the internal calibration with known concentration h (25 μ L/well) and signal antibody (50 μ L/well) were pipetted as duplicates. The concentration range of the IgE calibrators was 0 -216 ng/mL, rising from strip 5 -12.
The plate was incubated for 18 h at 2 -8 ° C in darkness. Cavities were washed three times with washing buffer. Then 100 μ L of chromogen solution was added to each well of the microplate. Subsequently, the plate was incubated for 30 min in dark at room temperature and the reaction was stopped by adding stopping solution (25 μ L/well). Following this the absorbance of the cavities were read at 450 nm using a spectrophotometer (Spectra Flour, TECAN, Crailsheim, Germany). Measured values were calculated using XLSTATPro (Addinsoft SARL, Paris, France) for a 2D evaluation. After subtracting the non-specifi c binding (as a blank) the net extinction E x is obtained for the estimation of x (IgE) in the samples according eq. [1a] .
To demonstrate the assay principle for unknown samples, the following samples were selected:
For testing the assay procedure three groups each of i.
the seven samples were prepared from IgE-free human serum. All sample groups contained the same amount of added IgE (50 ng/mL). Sample group 1a was without TA. Sample group 1b contained one concentration of TA (0.25 μ g/mL Omalizumab) and 1c the two-fold concentration of TA (0.50 μ g/mL Omalizumab).
Four samples of human serum which are not from ii.
Omalizumab therapy. Sample 2a was the original serum. Three more samples were prepared from this original serum by adding different amounts of Omalizumab: 2b with 0.188 μ g/mL, 2c with 0.375 μ g/mL and 2d with 3.000 μ g/mL. Four samples of human serum from Omalizumab therapy. iii. 3a: serum of patient A, treated with 450 mg Omalizumab; 3b: serum of the same patient A, treated with 300 mg Omalizumab. 4a: serum of patient B, treated with 300 mg Omalizumab; 4b: serum of patient B, treated with 150 mg Omalizumab. These samples were tested in the assay in a dilution of 1:20 with assay buffer.
All the samples were evaluated with the above described assay procedure in eight independent assays. The results are summarized in Table 1 . In all cases values were found within the expected range. Recovered antigen in dependence of added antigen formed always a linear function.
At fi rst the reliability of the internal calibration procedure was tested on 21 samples of known concentrations in the three sample groups 1a -c, each with seven identical samples. All samples contained the same amount of IgE, but different amounts of Omalizumab. For each group a separate assay was run, and the samples were put into the wells in duplicates. From the O.D. of the samples x a (h) was estimated and evaluated by linear regression according to equation: x a (h) = a + rec × h, yielding rec by the slope. Mean values ± standard deviations of these 14-fold determinations are shown in Table 1 . The assay determined in:
Sample group 1a (IgE-free serum with 50 ng/mL IgE): no i.
Omalizumab, 50.2 ± 1.1 ng/mL IgE and 97.4 % ± 8.3 % antigen recovery; Sample group 1b (IgE-free serum with 50 ng/mL IgE + 0.25 ii.
μ g/mL Omalizumab): 0.26 ± 0.02 μ g/mL Omalizumab, 30.9 ± 0.6 ng/mL free IgE x a and 52.3 % ± 2.0 % antigen recovery; Sample group 1c (IgE-free serum with 50 ng/mL IgE + 0.5 iii.
μ g/mL Omalizumab): 0.52 ± 0.03 μ g/mL Omalizumab, 21.1 ± 1.3 ng/mL free IgE x a and 35.3 % ± 1.5 % antigen recovery.
In the native serum sample 2a, no Omalizumab could be determined. Both 14. 4 In the serum samples 2b -d with added Omalizumab the measured IgE level and the antigen recovery is decreased. The measured Omalizumab concentrations are in the range of addition (see Table 1 After subtracting the experimental non-specifi c binding u the net extinction E x is obtained: E x = E -u. Then the inverse of eq. [1] was used for the estimation of x a (IgE) as shown in Table 1 , forming a linear graph with an constant value of free IgE = 31.2 ng/mL and a slope = rec = 0.185. This rec of the sample 3a was used now to determine its content of TA, calculated with the inverse of eq. [3] .
Discussion
As the example shows, coherent results are obtained for the measurement of free antigen and TA in the added samples. Furthermore, it was demonstrated in clinical studies with Omalizumab (TA)/IgE (antigen) that TA-containing samples Figure 3 Layout of the recovery ELISA microplate for sample measurement. Table 1 Results of measurements of several serum samples with the recover yELISA for Omalizumab (TA)/IgE (antigen).
Sample description
Replicates IgE, are measurable with recovery ELISA and this is a valuable aid in assessing treatment progress (6) . An alternative method for monitoring Omalizumab therapy was published in 2005. Hamilton et al. (7) developed a very special ELISA for free IgE using labeled FcqR1a (IgEreceptor) as the signal molecule and one ELISA for total IgE. But both these assays can only be used indirectly for Omalizumab level measurement. They did not measure the therapeutic antibody itself.
Beum et al. published a special method for therapy monitoring of another therapeutic antibody Rituximab (8) and Jilani et al. for the antibody Alemtuzumab (9) .
Apart from these specialized methods, the recovery ELISA could become a general assay concept valid for all therapeutic antibodies under certain preconditions. The most important optimization task of the recovery ELISA lies in the selection of appropriate assay conditions (10, 11) . Finally, an equation with inhibition for the assay evaluation must be applicable, which guarantees that the recovery (rec) is independent of the antigen concentration in the frame of experimental error. For the performance of the assay and the applicability of eq. [4] , it is necessary that the incubation period lasts until the response no longer changes. It takes at minimum 15 h. The reaction of the target protein (antigen) with the TA itself is fast, but slows down due to immobilization process at capture antibody. The recovery function:
is derived from [4] by rearranging. As a proof of principle, it was found that the reciprocal of K i from the 3D model according eq. [4] was found similar to the inhibition coeffi cient p 1 of the 2D model according eq. The Michaelis-Menten model was successfully applied to fi t the calibration curve of the ELISA for IgE. The O.D.
of 40 calibration samples containing IgE = x and TA = y to eq. [4] was approximated. All the regression parameters were evaluated with acceptable ranges of confi dence. This 3D evaluation of course is not suitable for practical daily performance.
Eq. [4] describes enzyme kinetics in the presence of a competing inhibitor. In solution, equilibrium was quickly reached and in a lower consecutive reaction, the product is formed and the enzyme was restored. The observations described seem to suggest, that in the solution, the enzymelinked antibody r and the therapeutic one y in competitive reaction for x reach equilibrium. In a slower process, a certain part of r x is bound by the anti-IgE capture antibody at the surface of the wells.
The dissociation of such complex from the surface is known to be very slow (12) . This irreversible part of the reactions favors also the phenomenal recovery model. But also the complex yx of IgE and TA may bind to the surface and displacement reactions may also be involved. Therefore, it can be assumed, that at the solid surface, the competitive equilibrium concentrations in the solution phase might be copied and refl ect the masking of IgE by TA.
Conclusions
In relation to the described immunoassay for Omalizumab (TA)/IgE (antigen), the preconditions mentioned above are fulfi lled and therefore, it corresponds to the principle of recovery ELISA.
For the practical implementation of this new assay principle, it is necessary to measure samples in the microplate with different additions of antigen. Therefore, a special microplate layout is used in the newly developed recovery ELISA test kits.
The recovery ELISA for IgE/Omalizumab is meanwhile marked with CE and manufactured in compliance with the directive 98/79/EC regarding in vitro diagnostic (BioTeZ Kit " RIO " , order No.: R111).
To check whether the recovery ELISA is a universal principle, other applications are examined. First prospective results were also found with a recovery ELISA for TNF-α / Adalimumab.
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